NCT00833040已完成2 期
A Multicenter, Randomized, Placebo-Controlled, Crossover Study for the Evaluation of the Safety, Tolerability, and Efficacy of ARX-F02 Compared to Placebo in the Treatment of Cancer Breakthrough Pain
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 34
- 试验地点
- 13
- 主要终点
- Time-weighted SPID30
研究概览
简要总结
The purpose of this research study was to evaluate ARX-F02 (Sufentanil NanoTab) versus placebo ("sugar" pill or inactive substance) in the management of breakthrough pain in cancer patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients 18 years of age or older with documented clinical history or evidence of a malignancy.
- •Patients must have sufficient pain to require at least the equivalent of 60 mg/day oral morphine, at least 25 mcg/hr transdermal fentanyl, at least 30 mg/day oxycodone, at least 8 mg/day oral hydromorphone for a week or longer.
- •Patient is experiencing 1 - 4 episodes of cancer breakthrough pain per day, on average but not necessarily every day, requiring use of an additional opioid analgesic.
- •Patient has a life expectancy of at least 3 months.
- •Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status rating <
- •Patient must be able to provide reliable documentation of pain intensity, pain relief, use of rescue medication, and global evaluation of treatment personally or with the help of a caregiver.
- •Patient must be able to enter simple commands on a Palm Pilot device, personally or with the help of a caregiver.
- •If patient is female and of childbearing potential she must have a negative urine pregnancy test at screening, and must use medically acceptable methods of birth control. Acceptable methods of birth control include oral or transdermal contraceptives, condom, spermicidal foam, IUD, progestin implant or injection, abstinence, vaginal ring, or sterilization of partner. The reason for non-childbearing potential, such as bilateral tubal ligation, bilateral oophorectomy, hysterectomy, or 1 year or more postmenopausal must be specified in the patient's CRF.
- •Patient must demonstrate the dexterity to handle the single-dose applicator that will be used for placing the NanoTab™ under the tongue.
- •Patient and/or caregiver must demonstrate ability to use the NanoTab™ retrieval tool.
- •There must be a caregiver in the home (or hospice) who will be present for at least 1 hour following each dose during titration.
- •Patient must provide written informed consent.
排除标准
- •Patients with uncontrollable or rapidly escalating pain.
- •Patients with a history of psychiatric disease or loss of cognitive function that would prevent patient from providing reliable study documentation.
- •Patients with oral mucositis or stomatitis.
- •Patients with a history of substance abuse within the past year.
- •Patients who are using intrathecal opioids.
- •Patients with underlying pulmonary disease such as sleep apnea or chronic obstructive pulmonary disease characterized by CO2 retention that is deemed clinically significant by the investigator.
- •Patients at risk of significant bradyarrhythmia, in the opinion of the Investigator, due to underlying heart disease.
- •Patients with abnormal chemistry or hematology that are deemed by the investigator to be clinically significant. Abnormalities that are cancer related should be documented.
- •Patients with clinically significant abnormality on the Screening ECG who, in the Investigator's opinion, should not participate in the study.
- •Patients who will be receiving chemotherapy or radiation treatment during the 3-week titration phase or 3-week double-blind phase that, in the Investigator's opinion, may dramatically alter the patient's pain level or response to pain medications.
- •Patients who are taking monoamine oxidase inhibitors (MAOIs), or have taken MAOIs within 14 days prior to enrolling in the study.
- •Patients who have participated in a clinical trial of an investigational drug or device within 30 days of screening visit.
- •Patients who, in the Investigator's opinion, should not participate in the study or may not be capable of following the study schedule or procedures for any reason.
- •Patients who are employees or family members of the Investigator, study center or AcelRx.
研究组 & 干预措施
Titration of sufentanil, the DBL sufentanil & PBO
Experimental
During the Titration Phase, patients titrated to the effective dosage of sublingual sufentanil NanoTab™(20, 30, 40, 60 or 80 mcg). One sublingual sufentanil NanoTab™ was taken as needed for breakthrough pain.
During the Double-Blind Phase, patients were then randomized to one of six treatment sequences, each of which included seven active doses of sublingual sufentanil (dosage determined in Titration Phase) and three placebo doses taken in random order. One NanoTab™ was taken as needed for breakthrough pain.
干预措施: Sublingual sufentanil NanoTabs™ and placebo NanoTabs™ (Drug)
结局指标
主要结局
Time-weighted SPID30
时间窗: 30 minutes after dosing
time-weighted SPID30 is the sum of the pain intensity difference (PID) over the 30 minute time period. A pain intensity score of 0 (no pain) to 10 (worse possible pain) is recorded at pre-dose, 10, 15, 30, 45, and 60 minutes post-dose. The pain score at each assessment time through 30 minutes is subtracted from the baseline pain score to provide the total sum score or SPID30. A higher SPID30 is better and indicates a reduction in pain intensity compared to the baseline score.
次要结局
未报告次要终点
研究者
研究点 (13)
Loading locations...
相似试验
已完成
2 期
A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Major Abdominal SurgeryMajor Upper or Lower Abdominal SurgeryNCT00718081Talphera, Inc88
已完成
2 期
A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN)Postherpetic NeuralgiaNCT01195636Xenon Pharmaceuticals Inc.70
已完成
2 期
Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver CancerAdult Primary Hepatocellular CarcinomaLocalized Resectable Adult Primary Liver CancerLocalized Unresectable Adult Primary Liver CancerRecurrent Adult Primary Liver CancerNCT01624285Jonsson Comprehensive Cancer Center20
撤回
2 期
Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid CarcinomaMedullary Thyroid CarcinomaNCT01736878Eanm Research Ltd
已完成
4 期
To Compare the Effectiveness of Suvorexant vs Placebo on Sleep Pressure in Hypertensives With InsomniaInsomniaHypertensionNCT02849184Jichi Medical University82